Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics (NASDAQ:AXSM) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 11 | 7 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 1 | 0 | 0 | 0 |
2M Ago | 6 | 2 | 0 | 0 | 0 |
3M Ago | 4 | 3 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $131.89, a high estimate of $190.00, and a low estimate of $103.00. This current average has increased by 6.52% from the previous average price target of $123.82.
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Vikram Purohit | Morgan Stanley | Raises | Overweight | $115.00 | $90.00 |
Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | - |
Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
Graig Suvannavejh | Mizuho | Raises | Buy | $109.00 | $108.00 |
Joon Lee | Truist Securities | Maintains | Buy | $150.00 | - |
Leonid Timashev | RBC Capital | Raises | Outperform | $128.00 | $123.00 |
David Hoang | Citigroup | Raises | Buy | $127.00 | $125.00 |
Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $190.00 | $180.00 |
Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | - |
Joel Beatty | Baird | Announces | Outperform | $108.00 | - |
Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | - |
Graig Suvannavejh | Mizuho | Lowers | Buy | $108.00 | $112.00 |
Yatin Suneja | Guggenheim | Raises | Buy | $125.00 | $110.00 |
Leonid Timashev | RBC Capital | Lowers | Outperform | $123.00 | $126.00 |
Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $103.00 | $108.00 |
Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $108.00 | - |
Graig Suvannavejh | Mizuho | Raises | Buy | $112.00 | $90.00 |
Ashwani Verma | UBS | Announces | Buy | $111.00 | - |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of 193.5% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -137.92%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -42.85%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -16.59%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below the industry average at 0.98, reflecting a lower dependency on debt financing and a more conservative financial approach.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AXSM